The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder.
The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo